Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cheryl Aber

Dermatology Aventura, FL Medical Doctor

NPI 1740275312 CMS profile 33449

20704 W Dixie Highway, Aventura, FL 33180

Open in the dashboard

General payments

$3,746

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cheryl Aber of Aventura, FL is reported in the CMS Open Payments database as having received $3,746 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,110 42
2024 General $431 20
2023 General $531 24
2022 General $381 18
2021 General $275 15
2020 General $253 12
2019 General $764 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cheryl Aber
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Cheryl Aber were reported at $1,110. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Cheryl Aber Dermatology median Middle half National median
2019 $764 $454 $129–$1,240 $163
2020 $253 $235 $81–$756 $114
2021 $275 $377 $108–$1,108 $132
2022 $381 $514 $143–$1,391 $149
2023 $531 $607 $159–$1,674 $160
2024 $431 $751 $204–$1,903 $164
2025 $1,110 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $705 35 payments
  2. Genzyme Corporation $504 18 payments
  3. Pfizer Inc. $413 18 payments
  4. Regeneron Healthcare Solutions, Inc. $394 16 payments
  5. Almirall LLC $341 18 payments
  6. Allergan Inc. $285 15 payments
  7. Novartis Pharmaceuticals Corporation $156 7 payments
  8. Galderma Laboratories, L.P. $134 7 payments
  9. Organon LLC $116 4 payments
  10. Lilly USA, LLC $113 5 payments
  11. Other $584 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,746 169 payments
Products named General payments · program years 2019–2025
  1. BOTOX $767 40 payments
  2. DUPIXENT Immunology $671 23 payments
  3. CIBINQO $338 14 payments
  4. Seysara $297 16 payments
  5. DUPIXENT Immunology And Inflammation $232 9 payments
  6. DUPIXENT Inflammation And Immunology $162 7 payments
  7. SKYRIZI $118 6 payments
  8. COSENTYX $99 4 payments
  9. TALTZ $81 4 payments
  10. EUCRISA $75 4 payments
  11. Other $1,241 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

156

Median for Dermatology: 534

Drug cost

$2,543

Median for Dermatology: $67,151

Branded share of claims

15.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 20 $559
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 24 $484
Mometasone Furoate Generic 22 $406
Triamcinolone Acetonide Generic 25 $387
Ketoconazole Generic 14 $290
Hydrocortisone Generic 25 $227
Mupirocin Generic 26 $190

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$44,391

Of which drugs: $3,239

Medicare patients

148

Average age 76

Services billed

991

95 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 51%
Ischemic heart disease 32%
Osteoporosis 27%
Diabetes 22%
Cancer 18%
Chronic kidney disease 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 11 11 $3,232

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $105
  • Regeneron Healthcare Solutions, Inc. $65
$170 — —
BOTOX
  • AbbVie, Inc. $160
$160 — —
CIBINQO
  • PFIZER INC. $69
$69 — —
SKYRIZI
  • AbbVie, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record